Search

Through personal narratives, pre-service teachers recount their experiences from a course based in Indigenous pedagogy within the Faculty of Education at the University of Victoria. These narratives were drawn from the assigned daily reflection journals of pre-service teachers. They highlight how their personal understandings of teaching and learning were transformed. In the context of a Lekwungen and Liekwelthout pole carving course, they developed a deep understanding of the Indigenous concepts of "Celhcelh"--the development of a sense of responsibility for personal learning within the context of a learning community; "Kat'il'a"--the act of becoming still--slowing down, despite an ingrained and urgent need to know and desire for busy-ness; "Cwelelep"--the discomfort and value of being in a place of dissonance, uncertainty and anticipation; and "Kamucwkalha"--the energy current that indicates the emergence of a communal sense of purpose. The writers share their personal reflections of these concepts and how they affected their views of teaching and learning.

The article reports the decision of the British Columbia Court of Appeal in the case "Contech Enterprises Inc. v. Vegherb LLC" in which the court held that license of intellectual property rights can be a security agreement in substance and mentions the PersonaI Property Security Act (PPSA).

The article discusses the implications in the Australian personal property security law reform; discusses the provisions under the Canadian Personal Property Security Act (PPSA); and mentions the influence of PPSA on personal property security law reform in Australia, New Zealand.

Canada's 41st general election was held on May 2, 2011. There were bitter disputes over the results in some ridings after certain candidates won their seats with razorthin margins. To determine once and for all who won and who lost, judicial recounts were ordered in four ridings: Montmagny-L'Islet-Kamouraska-Rivière-du-Loup, Etobicoke Centre, Nipissing-Timiskaming, and Winnipeg Centre. This article looks at the history of judicial recounts, the process that was used to examine the ballots in Montmagny-L'Islet-Kamouraska-Rivière-du-Loup, and Mr. Justice Gilles Blanchet's rulings on the disputed ballots. [ABSTRACT FROM AUTHOR]

Copyright of Canadian Journal of Counselling & Psychotherapy / Revue Canadienne de Counseling et de Psychothérapie is the property of Canadian Counselling & Psychotherapy Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The article focuses on the enactement of the comprehensive statutory regime by the Personal Property Security Act (PPSAs) to ensure the security interests in personal property in Canada. The regulation states that the license remains the property of the Crown. The bill also allows legislatures to have an option to prevent security interests in statutory license by specifying in the statute the license is not movable.

The article comments on the decision of the Supreme Court of Canada in the case of Soulos vs. Korkontzilas. In this case, the court held that the reversal of unjust treatment is not the only function of constructive trust remedy and its other function is to prevent a wrongful conduct such as breach of fiduciary obligation.

Discusses the reform in the bankruptcy law of Canada. Difference between the Bankruptcy and Insolvency Act RSC 1985 (BIA) and the Companies' Creditors Arrangement Act RSC 1985; Issues involved in commercial insolvency recommendations; Details of executory contracts; Provisions in the BIA.

In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem transplantation has been explored as a means to deepen responses and further improve survival however, its role remains controversial. This is particularly true in the era of novel agent induction and post-transplant maintenance therapy. The aim of this study was to use the Canadian Myeloma Research Group database and examine a large cohort of real-world patients comparing the outcomes of tandem versus single ASCT specifically in high-risk patients receiving novel agent-based induction and post-transplant maintenance. The data for this study was derived retrospectively from a comprehensive national-level database of Canadian patients with MM. High-risk cytogenetics was defined as presence of del17p, t(4;14), or t(14;16). Those receiving allogeneic transplant were excluded. Tandem transplantation was defined as a second ASCT performed consecutively without interim relapse or progression after first ASCT. Those with relapse or progressive disease within 3 months of completing a first transplant were excluded. We compared response depth, progression-free, and overall survival (OS) based on single or tandem transplantation procedures. The impact of covariates of interest was also assessed. A total of 381 patients with high-risk cytogenetics were identified. A total of 242 received single and 139 patients received tandem transplants. All received post-transplant maintenance. The most common induction regimen for these patients was cyclophosphamide, bortezomib, and steroids (CyBorD, 87%). Forty-one patients (10.8%) required reinduction prior to first ASCT. The best overall responses at any time were 98.3% (90.5% ≥ very good partial response [VGPR]) and 98.6% (89.9% ≥ VGPR) in the single and tandem ASCT groups, respectively. Survival outcomes were similar with the median progression-free survival for single or tandem ASCT of 35.2 and 35.3 months (P = .88) and the median OS were 92.6 and 88.9 months, respectively (P = .72). No statistically significant differences were seen based on type of cytogenetic abnormality or type of maintenance. This was confirmed on multivariate analysis. In the real-world setting, tandem ASCT does not improve outcomes for MM patients with high-risk cytogenetics. This may be driven by the use of effective pre- and post-ASCT therapies. The development of more potent induction and consolidation along with current nearly ubiquitous continuous maintenance therapies until disease progression does not support the use of a second high-dose procedure., (Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)

Background: Higher cumulative dose of bortezomib, a key component of Multiple Myeloma (MM) treatment regimens, has been shown to improve outcomes in MM patients, but must be balanced with toxicities including peripheral neuropathy. In this study, we studied the effect of cumulative bortezomib dose on survival, depth of response, and discontinuation rate in transplant ineligible MM patients., Patients and Methods: Data from 70 patients treated with Cyclophsophamide, Bortezomib, and Dexamethasone (CyBorD) in a single Canadian center were grouped according to above vs below median cumulative bortezomib dose and analyzed for progression-free survival (PFS), overall survival (OS), depth of response, and discontinuation rate., Results: There was a trend for lower discontinuation rate (45.7% vs. 68.6%, P = .052) and significantly lower rate of neuropathy-related discontinuation (5.7% vs. 22.9%, P = .035) in patients who received higher than 43.1 mg/m² of bortezomib. The higher-dose group showed a trend for higher rate of complete response (14.3% vs. 5.7%, P = .225) and significantly higher rate of very good partial response or better (77.1% vs. 51.4%, P = .024). There was significantly longer PFS (24.3 vs. 9.1 months, P = .012) and a trend for longer OS (22.4 vs. 61.3 months, P = .061) in the higher-dose group. In landmark analysis after 180 days, PFS (23.5 vs. 24.3 months, P = .941) and OS were similar in both groups., Conclusion: Higher cumulative bortezomib dose showed a lower rate of discontinuation, longer survival, and deeper response. Determining risk of treatment intolerance remains important for treatment., (Copyright © 2022 Elsevier Inc. All rights reserved.)

Background: The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood., Objective: We describe a local experience of the management of MM patients and report their outcomes during the current pandemic., Methods: All consecutive symptomatic MM patients seen at our center since 03/20 were evaluated., Results: A cohort of 156 patients diagnosed from 01/19 to 12/20 was analyzed to interrogate differences in presentation patterns. A total of 553 MM patients were seen and/or treated at Tom Baker Cancer Center in the year of 2020. From those, 47.1% (n = 261) were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Sixteen patients tested positive and data are presented. In addition, a decrease of 21.7% in the rate of new smoldering MM/MM diagnosis was observed in 2020 as compared to 2019. Further, an increase in deaths was also observed in 2020., Conclusions: Our study confirms an increase lethality for MM patients infected with SARS-CoV-2. A balance between safety and need for cancer control should be emphasized.

Recently, we introduced a novel measure of "average life span shortened" (ALSS) to improve comparability of premature mortality over time. In this study, we applied this novel measure to examine trends in premature mortality caused by hematological cancers in Canada from 1980 to 2015. Mortality data for Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia were obtained from the World Health Organization mortality database. Years of life lost was calculated according to Canadian life tables. ALSS was defined as the ratio between years of life lost and expected life span. Over the study period, age-standardized rates of mortality decreased for all types of hematological cancers. Our new ALSS measure showed favorable trends in premature mortality for all types of hematological cancers among both sexes. For instance, men with non-Hodgkin lymphoma lost an average of 23.7% of their life span in 1980 versus 16.1% in 2015, while women with non-Hodgkin lymphoma lost an average of 21.7% of their life span in 1980 versus 15.5% in 2015. Results from this study showed that patients with hematological cancers experienced prolonged survival over a 35-year period although the magnitude of these life span gains varied by types of hematological cancers., (© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)